Back to List View Graph View

Anaplastic Lymphoma Kinase (ALK)

ALK receptor tyrosine kinase is a receptor tyrosine kinase encoded by the ALK gene and is best known in medicine as a clinically important oncogenic target in several cancers, especially ALK-rearranged non-small cell lung cancer (NSCLC) and anaplastic large cell lymphoma.

Where the papers sit

9 papers from the last 6 months study Anaplastic Lymphoma Kinase (ALK) directly · updated from PubMed 9 Nov 2026

Study type 0 clinical trials · 2 observational · 1 human data · 4 preclinical · 2 unclassified

Themes one subject · 1 new direction

Those 9 are all about one subject.

  • ALK Translational Research

    ALK translational research spans targeted drugs, pharmacokinetics, treatment toxicity, clinical outcomes and disease biology. Alectinib-associated kidney injury, brigatinib dosing, entrectinib metabolism and real-world TKI use emphasize treatment optimization and safety. TRI-611 and lorlatinib extend investigation toward molecular degradation and ALK-mediated neuroinflammation. The collection has no single therapeutic direction, but consistently links ALK biology to clinical and preclinical applications.

    9 papers

NEW DIRECTION

ALK is implicated as a microglial driver of Parkinson-related neuroinflammation, not only as a cancer target

The MPTP-induced mouse model of Parkinson’s disease treated with lorlatinib assumes ALK primarily as a therapeutic target in ALK-driven malignancy, whereas this study found that ALK phosphorylation was concentrated in microglia and that ALK inhibition reduced neuroinflammation, oxidative stress, dopaminergic neuronal loss, and motor impairment. This extends ALK into a disease mechanism outside cancer and identifies it as a potential target for neurodegenerative disease intervention 42208344May.

Papers

The 9 papers from the last 6 months that study Anaplastic Lymphoma Kinase (ALK) directly, newest first, by theme and by study type. Study types come from PubMed publication types and MeSH headings.

By theme

ALK Translational Research (9)
  1. Severe, reversible alectinib-induced acute kidney injury requiring dialysis in an elderly patient with metastatic non-small cell lung cancer. BMJ case reports · 22 Sept 2026 PMID 42772921
  2. TRI-611, a selective, brain-penetrant molecular glue degrader of ALK. Nature · 10 Sept 2026 PMID 42717093
  3. Varying Cancer Drug Doses to Balance Tumor Control and Resistance Evolution. Cancer research · 2 Sept 2026 PMID 42682083
  4. Physiologically Based Pharmacokinetic Model of Brigatinib in Healthy Volunteers and Patients With Cancer. CPT: pharmacometrics & systems pharmacology · 21 Jul 2026 PMID 42481921
  5. Real-World Clinical and Economic Consequences of Next-Generation Anaplastic Lymphoma Kinase-Positive (ALK +) Tyrosine Kinase Inhibitors (TKIs) in Patients with TKI-Naïve ALK + Metastatic Non-Small Cell Lung Cancer in the United States. Advances in therapy · 9 Jul 2026 PMID 42423952
  6. [Translated article] Real world outcomes of first-line pembrolizumab in metastatic non-small-cell lung cancer. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 12 Jun 2026 PMID 42285782
  7. Evaluation of the Effects of Nicardipine on Entrectinib Metabolism in vitro and in Rats. European journal of drug metabolism and pharmacokinetics · 2 Jun 2026 PMID 42230445
  8. Oral manifestations of anaplastic large cell lymphoma: clinicopathological features and main immunophenotypic findings of 3 cases. Journal of hematopathology · 29 May 2026 PMID 42213355
  9. Lorlatinib protects dopaminergic neurons by inhibiting ALK-mediated neuroinflammation in a mouse model of Parkinson's disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 28 May 2026 PMID 42208344

By study type

Observational studies and case reports (2)
  1. Severe, reversible alectinib-induced acute kidney injury requiring dialysis in an elderly patient with metastatic non-small cell lung cancer. BMJ case reports · 22 Sept 2026 PMID 42772921
  2. Oral manifestations of anaplastic large cell lymphoma: clinicopathological features and main immunophenotypic findings of 3 cases. Journal of hematopathology · 29 May 2026 PMID 42213355
Human data, design not indexed (1)
  1. Physiologically Based Pharmacokinetic Model of Brigatinib in Healthy Volunteers and Patients With Cancer. CPT: pharmacometrics & systems pharmacology · 21 Jul 2026 PMID 42481921
Preclinical: animal, cell and lab studies (4)
  1. TRI-611, a selective, brain-penetrant molecular glue degrader of ALK. Nature · 10 Sept 2026 PMID 42717093
  2. Varying Cancer Drug Doses to Balance Tumor Control and Resistance Evolution. Cancer research · 2 Sept 2026 PMID 42682083
  3. Evaluation of the Effects of Nicardipine on Entrectinib Metabolism in vitro and in Rats. European journal of drug metabolism and pharmacokinetics · 2 Jun 2026 PMID 42230445
  4. Lorlatinib protects dopaminergic neurons by inhibiting ALK-mediated neuroinflammation in a mouse model of Parkinson's disease. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie · 28 May 2026 PMID 42208344
Unclassified: not yet indexed with MeSH (2)
  1. Real-World Clinical and Economic Consequences of Next-Generation Anaplastic Lymphoma Kinase-Positive (ALK +) Tyrosine Kinase Inhibitors (TKIs) in Patients with TKI-Naïve ALK + Metastatic Non-Small Cell Lung Cancer in the United States. Advances in therapy · 9 Jul 2026 PMID 42423952
  2. [Translated article] Real world outcomes of first-line pembrolizumab in metastatic non-small-cell lung cancer. Farmacia hospitalaria : organo oficial de expresion cientifica de la Sociedad Espanola de Farmacia Hospitalaria · 12 Jun 2026 PMID 42285782